Q2 EPS Estimates for UroGen Pharma Boosted by HC Wainwright

UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) - HC Wainwright lifted their Q2 2025 EPS estimates for UroGen Pharma in a research report issued on Thursday, May 22nd. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.74) per share for the quarter, up from their previous estimate of ($0.75). HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for UroGen Pharma's current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for UroGen Pharma's Q3 2025 earnings at ($0.65) EPS, Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.95) EPS, Q1 2026 earnings at ($0.63) EPS, Q2 2026 earnings at ($0.56) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.45) EPS and FY2026 earnings at ($2.14) EPS.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The company had revenue of $20.25 million during the quarter, compared to analyst estimates of $22.71 million.

Several other research analysts have also recently weighed in on the stock. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 price target on shares of UroGen Pharma in a report on Thursday, May 8th. The Goldman Sachs Group cut their target price on shares of UroGen Pharma from $16.00 to $3.00 and set a "neutral" rating for the company in a research report on Thursday, May 22nd. LADENBURG THALM/SH SH began coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They set a "buy" rating and a $31.00 price target for the company. Guggenheim lowered their price objective on shares of UroGen Pharma from $40.00 to $15.00 and set a "buy" rating for the company in a research note on Friday. Finally, Scotiabank began coverage on shares of UroGen Pharma in a research note on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 price objective for the company. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, UroGen Pharma currently has a consensus rating of "Moderate Buy" and a consensus price target of $27.43.

UroGen Pharma Stock Performance

Shares of NASDAQ URGN traded down $0.26 during mid-day trading on Monday, hitting $3.93. The company had a trading volume of 2,683,096 shares, compared to its average volume of 680,654. The company has a market capitalization of $181.20 million, a price-to-earnings ratio of -1.25 and a beta of 0.66. UroGen Pharma has a 1 year low of $3.42 and a 1 year high of $20.70. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The stock's 50-day moving average price is $9.88 and its 200-day moving average price is $10.59.

Institutional Trading of UroGen Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in URGN. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of UroGen Pharma by 216.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company's stock valued at $48,227,000 after buying an additional 2,983,368 shares during the last quarter. RTW Investments LP boosted its stake in shares of UroGen Pharma by 1.3% during the 4th quarter. RTW Investments LP now owns 3,834,794 shares of the company's stock worth $40,841,000 after acquiring an additional 47,447 shares during the last quarter. RA Capital Management L.P. purchased a new position in shares of UroGen Pharma during the 1st quarter worth $35,461,000. Vestal Point Capital LP lifted its stake in shares of UroGen Pharma by 32.1% during the 1st quarter. Vestal Point Capital LP now owns 2,152,957 shares of the company's stock valued at $23,812,000 after buying an additional 522,957 shares in the last quarter. Finally, Toronto Dominion Bank purchased a new position in shares of UroGen Pharma during the 4th quarter valued at $18,628,000. Hedge funds and other institutional investors own 91.29% of the company's stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.